

## REVIEW

# Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians

Pedro Rosa-Neto<sup>\*1,2</sup>, Ging-Yuek Robin Hsiung<sup>†3</sup> and Mario Masellis<sup>†4,5,6</sup> on behalf of the CCDDT4 participants

### Abstract

Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a rapidly evolving field. Here, we provide a review and recommendations regarding the use of fluid biomarkers in clinical practice as discussed at the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCDDT4) convened in Montreal, 4 to 5 May 2012. At present, there is no consensus regarding the optimal methodology for conducting quantification of plasma amyloid-beta ( $A\beta$ ) peptides. In addition, since there is insufficient evidence supporting clinical applications for plasma  $A\beta$ -peptide measures, the CCDDT4 does not recommend plasma biomarkers either for primary care or for specialists. Evidence for CSF  $A\beta_{1-42}$ , total tau and phosphorylated tau in the diagnosis of Alzheimer pathology is much stronger, and can be considered at the tertiary care level for selected cases to improve diagnostic certainty, particularly in those cases presenting atypical clinical features.

### Introduction

Examination of biological fluids provides quantitative information regarding biosynthesis, concentration and kinetics of biomarkers of interest to dementias as well as their respective metabolites. Today high-throughput analytical platforms are available for detailed analysis of fluid biomarkers, and at some point in the near future advanced proteomics techniques will possibly reveal signatures for all neurodegenerative diseases. These technological advances ultimately bring the promise of preclinical diagnosis of dementias using fluid biomarkers.

Significant developments have been obtained with quantification of cerebrospinal fluid (CSF) and plasma concentrations of amyloid beta ( $A\beta_{1-42}$ ), total tau (t-tau) and phosphorylated tau (p-tau) in the 181-threonine position [1,2]. However, despite favorable results obtained from large cohorts of dementia patients, translation of these technological advances into diagnostic methods is

limited by important factors such as reliability (that is, variability across laboratories) and accuracy (that is, inter-individual biological variability). Different from previous reviews on this topic, the present paper aims to summarize the fluid biomarker literature and to provide recommendations to physicians regarding the clinical utility of these novel techniques in Canada.

### Theoretical framework for using biomarkers in the diagnosis of dementia

A biomarker is defined as a 'characteristic that is objectively measured and evaluated as an indicator of normal biology, pathological process, or pharmacologic responses to a therapeutic intervention' [3]. Specifically, diagnostic or core biomarkers express measures of the underlying molecular pathology of a disease. In Alzheimer's disease (AD), biomarkers are generally classified as biomarkers of amyloid accumulation and biomarkers of neurodegeneration [4]. Core AD biomarkers reflect amyloid pathology ( $A\beta_{1-40}/A\beta_{1-42}$  extracellular accumulation) or intracellular deposit of neurofibrillary tangles (hyperphosphorylated tau inclusions) [3,5]. As such, biomarkers serve to identify in living individuals a variety of neuropathological features previously detected only by the analysis of specimens from biopsy or necropsy [6-8]. The availability of biomarkers for

\*Correspondence: pedro.rosa@mcgill.ca

<sup>1</sup>McGill Centre for Studies in Aging, 6825 LaSalle Boulevard, Verdun, QC H4H 1R3  
Full list of author information is available at the end of the article

<sup>†</sup>Contributed equally.

quantifying *in vivo* AD pathology (AD-P) has propelled advances in the understanding of AD as a dynamic clinicopathological entity. In contrast with the cross-sectional nature of neuropathology, biomarker assessments allow for longitudinal observations necessary to describe the temporal progression of neuropathology in neurodegenerative diseases [9]. Indeed, the value of imaging or fluid biomarkers for supporting the diagnosis of AD in living individuals has been acknowledged in the 2011 National Institute on Aging–Alzheimer’s Association criteria [9].

### Neurobiology of cerebrospinal fluid biomarkers for Alzheimer’s disease

In the past two decades, research in AD has elaborated a construct called the amyloid cascade hypothesis, which posits that a defect in A $\beta$ -peptide metabolism, a major chemical constituent of amyloid plaques, triggers a downstream cascade of neurodegenerative events leading to dementia [10-12]. This amyloidocentric disease model supports the basis for the classification of biomarkers as indicators of amyloid deposition or evidence of neurodegeneration (see Table 1).

### Cerebrospinal fluid biomarkers of amyloid accumulation

Biomarkers of amyloid accumulation refer to indices of brain amyloid deposition obtained using either positron emission tomography (PET) or analysis of CSF or plasma. While PET and amyloid agents (Table 1) quantify abnormal accumulation of A $\beta$  peptides as amyloid plaques, declines in CSF concentrations provide an index of A $\beta$ <sub>1-42</sub> retention in the brain. These methods constitute powerful means for *in vivo* detection of pathological A $\beta$ <sub>1-42</sub> aggregation and deposition in the brain tissue [2,13].

Mega-aggregates of A $\beta$  peptide form amyloid plaques in AD. A $\beta$ <sub>1-40</sub>/A $\beta$ <sub>1-42</sub> peptides result from the proteolysis of an integral membrane protein called amyloid precursor protein (APP). In the membrane, APP is differentially cleaved via nonamyloidogenic and amyloidogenic proteolytic pathways (Figures 1 and 2). In the nonamyloidogenic pathway, APP is sequentially cleaved by an alpha-secretase (a disintegrin and metalloprotease domain 10) and a gamma-secretase, precluding formation of the amyloidogenic peptides and leading to the release of soluble peptides (APP $\alpha$ ) into the extracellular space. In contrast, the amyloidogenic

**Table 1. Biomarkers for diagnosis of dementias**

Neuropathological process	Process of interest	Method	Outcome	Interpretation
Amyloid deposition	Fibrillar amyloid availability	[ <sup>11</sup> C]Pittsburgh compound B PET	Increased brain retention	Amyloid deposition <sup>a</sup>
	Fibrillar amyloid availability	[ <sup>18</sup> F]Florbetapir PET	Increased brain retention	Amyloid deposition <sup>a</sup>
	Fibrillar amyloid availability	[ <sup>18</sup> F]Florbetapen PET	Increased brain retention	Amyloid deposition <sup>a</sup>
	Fibrillar amyloid availability	[ <sup>18</sup> F]Flutemetamol PET	Increased brain retention	Amyloid deposition <sup>a</sup>
	A $\beta$ <sub>1-42</sub> CSF concentrations	Lumbar puncture	Declined in CSF concentration	Amyloid deposition [2,4,5]
	A $\beta$ <sub>1-42</sub> serum levels	Lumbar puncture	Declined in serum concentration	Amyloid deposition [2,4,5]
Neurodegeneration (downstream)	Brain metabolism or perfusion	[ <sup>18</sup> F]FDG PET or [ <sup>99</sup> Tc]HMPAO/ECD SPECT	Brain hypometabolism/perfusion in parietotemporal regions	Synaptic depletion <sup>a</sup>
	Total tau CSF concentrations	Lumbar puncture	Increased CSF concentration	Cell death [2,4,5]
	Tau-181 CSF concentrations	Lumbar puncture	Increased CSF concentration	Tau phosphorylation [2,4,5] <sup>b</sup>
	Brain atrophy	MRI	Decreased volume loss	Atrophy <sup>a</sup>
	Fibrillar tau accumulation	PET	Increased of retention	Tangle deposition <sup>a</sup>
Non-Alzheimer’s disease biomarkers	Brain lesions	MRI	Exclusion of alternative pathologies	Tumor, cerebrovascular disease <sup>a</sup>
	Brain metabolism or perfusion	[ <sup>18</sup> F]FDG PET or [ <sup>99</sup> Tc]HMPAO/ECD SPECT	Brain hypometabolism/perfusion in occipital regions or asymmetric frontotemporal regions	Diagnoses of LBD or FTD, respectively <sup>a</sup>
	Dopamine transporter availability	[ <sup>123</sup> I]Ioflupane (DAT) SPECT	Reduced uptake in basal ganglia	Reduction of dopamine transporters typical of LBD and other Parkinsonian syndromes <sup>a</sup>
	Inflammation	FLAIR MRI	Increased T2* signal	Parenchymal lesion <sup>a</sup>
	Hemosiderin	Susceptibility MRI	Loss on gradient-recalled echo	Hemosiderin leakage and macrophages in the brain parenchyma <sup>a</sup>

A $\beta$ <sub>1-42</sub>, amyloid-beta; CSF, cerebrospinal fluid; DAT, DopAmine Transporter; FDG, fluorodeoxyglucose; FLAIR, fluid attenuated inversion recovery; FTD, frontotemporal dementia; HMPAO/ECD, (99mTc) exametazime, (99mTc) -ethylcysteinate dimer; LBD, Lewy body dementia; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, Single-photon emission computed tomography. <sup>a</sup>See associated Canadian Consensus Conference on Diagnosis and Treatment of Dementia publications on biomarkers.

pathway, which refers to the sequential APP proteolysis (cleavage) by the enzymes beta-secretase (beta-site APP cleaving enzyme) and gamma-secretase, results in secretion of insoluble ( $A\beta_{1-40}/A\beta_{1-42}$ ) peptides into the extracellular space. Both  $A\beta_{1-40}$  and  $A\beta_{1-42}$  are hydrophobic and tend to form aggregates in aqueous environments. Once in the extracellular space,  $A\beta_{1-42}$  molecules undergo a massive aggregation process, which generates an amyloid plaque. Importantly, neurotoxic soluble  $A\beta_{1-42}$  aggregates (oligomers) are transiently formed during the process of plaque formation [14]. Possibly, oligomeric forms of  $A\beta$  are increased in the CSF of AD patients [15-18]. The toxicity of  $A\beta_{1-42}$  oligomers


has been extensively demonstrated by numerous studies (see [12]).

From the biomarker perspective, while amyloid PET agents detect increases of brain  $A\beta$ -peptide amyloidosis, CSF measures detect declines in  $A\beta_{1-42}$  concentrations. In fact,  $A\beta_{1-42}$  CSF concentrations and amyloid load detected by [ $^{11}C$ ]Pittsburgh compound B PET are correlated in an exponential fashion [19,20]. Low  $A\beta_{1-42}$  CSF concentrations in AD and mild cognitive impairment (MCI) are believed to be due to progressive brain retention of  $A\beta$ -peptide moieties in the form of amyloid plaques.

### Plasma biomarkers of amyloid accumulation

Although several plasma biomarkers – including plasma concentration of clusterin, C-reactive protein and acetylcholinesterase – have been tested in the context of dementia, core AD plasma biomarkers constitute a less invasive alternative for lumbar punctures [21,22]. Plasma  $A\beta_{1-42}$  levels or the  $A\beta_{1-42}/A\beta_{1-40}$  ratio have been studied in AD and MCI as well as in at-risk populations using enzyme-linked immunosorbent assays and multiplex platforms [23,24]. In general, these results show elevated  $A\beta_{1-42}$  or  $A\beta_{1-42}/A\beta_{1-40}$  ratio plasma concentrations in asymptomatic carriers of familial AD mutations (APP, PS1, and PS2) as well as patients with Down syndrome [25,26]. In cases of sporadic AD, there is evidence suggesting that low plasma levels of  $A\beta_{1-42}$  or  $A\beta_{1-42}/A\beta_{1-40}$  ratios characterize individuals with AD [24,27] (Figure 2). However, there is no correlation between  $A\beta_{1-42}$  or  $A\beta_{1-40}$  plasma and CSF [28].

Overall, these results need to be replicated due to disagreement between studies, although a recent meta-analysis of plasma core biomarkers in AD indicates that  $A\beta_{1-42}/A\beta_{1-40}$  predicts progression to dementia [29]. Methodological limitations in terms of sampling and analysis require further validation and standardization (for further details see [29,30]). At the present state of development, biomarkers are not yet suitable for clinical applications.




**Figure 1. Biochemical pathways associated with core biomarkers for Alzheimer's disease.** Biochemical pathways associated with the core biomarkers for Alzheimer's disease (AD) in the intracellular, membrane, extracellular, cerebrospinal fluid (CSF) and plasma compartments. Left: intracellular production of the amyloid precursor protein (APP), which is an integral part of the plasma membrane. APP is metabolized by a nonamyloidogenic (blue arrows) and an amyloidogenic pathway (red arrows). Right (neurodegeneration): an increased proportion of phosphorylated tau protein over nonphosphorylated tau protein at the threonine located at position 181 (p-tau-181) and position 231 (p-tau-231). While increased p-tau-181 and p-tau-231 in the CSF indicates hyperphosphorylation, total tau conveys cell death.  $A\beta$ , amyloid-beta; ADAM, a disintegrin and metalloproteinase; BACE, beta-site APP cleaving enzyme; sAPP, soluble amyloid precursor protein.


### Cerebrospinal fluid biomarkers of neurodegeneration

According to the amyloid cascade hypothesis, a decline in brain function revealed by biomarkers of neurodegeneration occurs as a result of amyloid toxicity, although the mechanisms linking amyloid pathology and neurodegeneration remain elusive [12]. Currently, [ $^{18}F$ ] fluorodeoxyglucose PET, magnetic resonance imaging (MRI) volumetry, and CSF t-tau or p-tau are the most relevant biomarkers of neurodegenerative processes present in patients with AD-P [4].

t-tau and p-tau constitute the classic AD CSF biomarkers for neurodegeneration (Figure 3). The tau



**Figure 2. Amyloid precursor protein metabolism and biomarker of amyloid pathology.** Schematic representation of amyloid precursor protein (APP) metabolism and biomarker of amyloid pathology in various of the intracellular, membrane, extracellular, cerebrospinal fluid (CSF) and plasma compartments. Color pallet indicates processes that have increased, declined or remained unchanged in Alzheimer's disease (AD). Note that in AD higher amyloid-beta ( $AB_{1-42}$ ) retention in the extracellular compartment (brain tissue) due to peptide aggregation leads to declines of  $AB_{1-42}$  in the CSF. In the plasma, it is debatable whether declines are present in individuals with AD.



**Figure 3. Biomarkers of tau pathology.** Schematic representation of biomarkers of tau pathology in in the intracellular, membrane, extracellular, cerebrospinal fluid (CSF) and plasma compartments. Color pallet indicates processes that have increased, declined or remained unchanged in Alzheimer's disease (AD). It has been proposed that the leakage of tau into the extracellular and CSF space is secondary to brain damage. Note in AD the increased concentrations of phosphorylated tau in all compartments. p-tau-181, phosphorylated tau protein at the threonine located at position 181; p-tau-231, phosphorylated tau protein at the threonine located at position 231.

protein is a constituent of neuronal microtubules, which are cell structures responsible for the motility of proteins and organelles within the neuron [31]. The functional expression of microtubules is modulated via phosphorylation of numerous serine and threonine residues (phosphorylation sites) present in the tau protein [5]. In AD, abnormal tau hyperphosphorylation is observed within neurons as neurofibrillary tangles or

dystrophic neurites present in neuritic plaques [32] (Figures 1 and 2). In MCI, concentrations of t-tau and p-tau in the 181-threonine position are elevated by 30–40%, while elevations up to 40–50% are seen in AD patients [33,34]. Synaptic injury or cellular death contributes to the leakage of t-tau and p-tau to the extracellular space. In fact, the CSF t-tau concentration is also increased in patients with encephalitis, trauma and

stroke [35-37]. The CSF tau concentration is useful for distinguishing AD patients from control subjects as well as from non-AD forms of dementia, although overlap at the level of pathology often exists [38,39].

Despite numerous threonine and serine phosphorylation sites present in tau protein, AD is best characterized by hyperphosphorylation at amino acid positions 181 or 231 [40]. p-tau in the 181-threonine position or in the 231-threonine position is specific for AD-P [40].

#### Progression of biomarkers during the course of the disease: dynamic biomarker of AD pathological cascade

Cross-sectional and longitudinal biomarker data provided the empirical basis for an AD model called the dynamic biomarker of AD pathological cascade. Proposed by Jack and collaborators, this model is widely accepted by the research community as a model of biomarker progression from the asymptomatic to dementia phases of AD [4]. The dynamic biomarker of AD pathological cascade hypothesis incorporates the entire clinical spectrum of AD comprising preclinical, MCI due to AD, and dementia stages as well as their specific biomarker signatures. Moreover, biomarker abnormalities are assumed to act as a surrogate for progressive neuropathological changes and follow a nonlinear progression, as shown in Figure 4. Similar to the amyloid cascade hypothesis, the dynamic biomarker of AD pathological cascade model assumes amyloid accumulation as an early event leading to a cascade of successive neurodegenerative processes (that is, tau pathology, synaptic depletion and cell loss) resulting in dementia [4]. The dynamic biomarker of AD pathological cascade model predicts decline of  $A\beta_{1-42}$  followed by


sequential tissue functional abnormalities (hypometabolism) and release of tau and p-tau in the CSF, and brain atrophy detectable by MRI. This model also proposes that memory and functional declines occur as a function of neurodegeneration [4].

#### Methods

A PubMed-based literature systematic review focusing on fluid biomarker peer-reviewed papers published since 2000 was drafted and subsequently reformatted in order to fit approximately 100 references and 4,000 words. Evidence-based fluid biomarker recommendations were discussed in the context of Canadian clinical practice during the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) [41,42]. CCCDTD4 recommendations were based on panel consensus following GRADE working group recommendations [43]. The methodology for grading evidences was based on those detailed elsewhere [41,42].

#### Methodological recommendations for cerebrospinal fluid sampling

Fluid biomarker concentrations are typically low and vulnerable to manipulation and sampling. Considerable variability in absolute concentrations and cutoff values of AD biomarkers has been found between different centers using the same assay [44]. In principle, the lumbar puncture procedure should follow a standard operating procedure to minimize the chances of false positive results. The best practices for CSF sampling and analysis remain a work in progress. Standard operating procedures for the xMAP multiplex platform (Luminex, Austin, TX, USA) have recently shown an intra-laboratory variation in the order of 5% and



**Figure 4. Dynamic biomarkers of Alzheimer's disease pathological cascade.** The dynamic biomarkers of Alzheimer's disease pathological cascade, as proposed by Jack and collaborators. This model predicts a preclinical and mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) characterized by predominance of amyloid pathology and a dementia phase characterized by amyloid pathology, neurodegenerative changes and subclinical cognitive impairment. Adapted from [4].

inter-laboratory variation between 10 and 20% [45]. The Alzheimer's Biomarkers Standardization Initiative recommendations for CSF biomarker are summarized in Table 2 [46]. These techniques are available for clinicians in commercial and research settings in the USA and Europe.

### Evidence of cerebrospinal fluid biomarkers in the clinical setting

#### Cerebrospinal fluid biomarkers in Alzheimer's disease

Much research has occurred over the past decade in terms of the development and validation of CSF biomarkers for the diagnosis of AD and related dementias. CSF is considered a good source of biomarkers for neurodegenerative diseases since pathological brain changes are expected to be reflected in

the CSF owing to its constant contact with cerebral tissue [47].

The most comprehensively studied CSF biomarker in AD is the measurement of  $A\beta_{1-42}$  since it is the main component of the amyloid plaques seen in AD. The  $A\beta$ -peptide metabolism in CSF has recently been examined in a study using isotope labeling coupled with mass spectrometry analysis [48]. The average fractional synthesis rate of  $A\beta$  in CSF was calculated as 7.6% while the fractional clearance rate was 8.3%, implying that production and clearance rates were not significantly different in healthy adults [48]. The utility of biomarkers in the diagnosis of AD and differentiation from other dementias have been reviewed extensively [40]. AD patients' CSF typically exhibits low  $A\beta_{1-42}$  concentrations and high levels of t-tau and p-tau in the 181-threonine

**Table 2. Summary of Alzheimer's Biomarkers Standardization Initiative recommendations for Alzheimer's disease biomarker testing**

Alzheimer's Biomarkers Standardization Initiative recommendations		
1	Computed tomography or MRI performed before LP	LP should not be performed in cases where there is high intracranial pressure or where there is a mass lesion in the brain
2	Concomitant medication	LP should not be performed in patients treated with anticoagulants (for example, warfarin). Treatment with platelet aggregation inhibitors is not a contraindication
3	Diurnal variation	No diurnal variation
4	CSF gradient/volume	No gradient observed. No requirement for a certain fraction. Minimum volume of 1.5 ml
5	Meal consumption	No need for fasting
6	Position	LP may be performed with the patient either sitting or lying down. The position of the patient does not affect the results
7	Location	Vertebral body L3 to L5. The incision point of the needle (L3 to L4 or L4 to L5) does not affect the results
8	Disinfection/anesthesia	Disinfection will reduce the risk of local infection. Local anesthetics introduce a risk of adverse effects, but can be given to patients who worry about local pain during LP
9	Needle	Use a small diameter (0.7 mm and 22 G), preferably nontraumatic needle. A small-gauge needle will make a smaller hole in the dura, aiding healing, and an atraumatic needle will reduce the chance of blood contamination in the CSF
10	Rest	Leave the patient to rest for half an hour after LP. Prolonged bed rest or other procedures will not influence the risk of post-LP headache
11	Tubes and aliquotation (type, volume, homogeneity)	Each laboratory should use the same polypropylene tube. Glass or polystyrene tubes should in no circumstances be used. Tubes of the smallest volume should be used, and these should be filled to at least 50% of their volume
12	Documentation of sampling/aliquotation	It is important to have carefully recorded and validated details concerning each stored sample so that any investigator when using these samples has a precise history of the sample
	Centrifugation (speed and temperature)	Centrifugation only required for visually hemorrhagic samples. Centrifuge as soon as possible – within 2 hours of LP (on site or at nearest laboratory). Speed has no effect; however, recommend 2,000×g for 10 minutes at room temperature (controlled)
13	Time and temperature before storage	Samples may be sent by regular post (transport 5 days).
14	Method of freezing (liquid nitrogen, dry ice, slow freezing at -20°C or -80°C)	Freezing at -80°C for storage. No difference between methods of freezing
15	Length of storage (when frozen)	Storage at -20°C for less than 2 months. Note: no evidence of any effect for up to 2 years at -80°C.
16	Number of freeze/thaw cycles	Limit the number of freeze/thaw cycles to one or two
17	Interfering substances (hemolysis)	Traumatic LP: Discard first 1 to 2 ml. Samples with an erythrocyte count of 500/ml should not be used without centrifugation

Summary of Alzheimer's Biomarkers Standardization Initiative recommendations for pre-analytical and analytical aspects for Alzheimer's disease biomarker testing in cerebrospinal fluid. Adapted from [7]. CSF, cerebrospinal fluid; LP, lumbar puncture; MRI, magnetic resonance imaging.

position. This characteristic pattern is regarded as the signature profile of AD in CSF [40].

Amalgamation of data from the Alzheimer Disease Neuroimaging Initiative studies generated a model for the temporal ordering of AD biomarkers, which suggests that A $\beta$  amyloid biomarkers (such as CSF A $\beta_{1-42}$  or PET amyloid imaging) are the first to become abnormal, followed by changes in neurodegenerative biomarkers (CSF t-tau, p-tau, [ $^{18}$ F]fluorodeoxyglucose PET, and structural MRI) with the onset of clinical symptoms [49,50]. These findings have been confirmed in a number of cross-sectional studies and prospective cohorts [39,51,52], including several with pathological confirmation of the diagnosis [53]. When the diagnosis of dementia was ambiguous on the basis of clinical presentation alone, CSF biomarkers improved diagnostic accuracy, and correlated with autopsy confirmation in up to 82% of cases [54]. In another study applying CSF biomarkers in a specialized dementia clinic, knowledge of CSF biomarker profiles changed the diagnosis in 10% of the cases, and confidence in the diagnosis increased for one-third of the patients [55].

Using a ratio of either p-tau/A $\beta_{1-42}$ , or t-tau/A $\beta_{1-42}$  in differentiating AD from other dementias, the sensitivity was reported to be up to 92%, and specificity 86%, with an overall accuracy of 90% for the presence of pathologic neuritic plaque in the brain [53]. Accuracy was particularly high using this combination of CSF biomarkers in differentiating AD from frontotemporal dementia (FTD), progressive supranuclear palsy, Parkinson's disease with dementia (PDD) and corticobasal degeneration, but not as clear for dementia with Lewy bodies (DLB) and vascular dementia (VaD), possibly because of the propensity for mixed-pathology in DLB and VaD (see below). Patients with Creutzfeldt-Jakob disease demonstrated extremely high CSF t-tau with relatively normal levels of p-tau and A $\beta_{1-42}$  [56].

#### **Cerebrospinal fluid biomarkers in MCI – predicting conversion to Alzheimer's disease**

An important utility of CSF biomarkers is to predict the likelihood of conversion from MCI to AD dementia. A number of studies support the notion that the CSF signature profile of AD – comprising low A $\beta_{1-42}$  and high t-tau or p-tau – has good diagnostic accuracy in terms of distinguishing between normal ageing and AD (>85%) and a positive predictive value (>90%) in terms of predicting conversion to dementia in patients with MCI [57]. Large-scale longitudinal studies of MCI cohorts consistently demonstrate that the presence of this AD signature in CSF has a good diagnostic accuracy (>80%) in discriminating patients with MCI who progress to AD (MCI converters) from those who remain cognitively stable (MCI-stable patients) and healthy controls [57], as

well as those MCI patients who progress to non-AD dementias [58].

These findings have been replicated by different research groups worldwide [51,59], and further reinforced by meta-analyses of different datasets [60]. The converging evidence thus suggests that the presence of this AD signature in the CSF is a strong predictor of dementia outcome due to AD-P, with an increased odds ratio of up to 20 [61]. MCI patients who convert to AD generally have a CSF biomarker pattern indistinguishable from that found in patients with dementia of the AD type. CSF t-tau and p-tau are robust predictors of AD outcome, and are also associated with a more rapid progression from MCI to AD [62]. These findings can be applied to enrich clinical trials via recruitment of MCI subjects who are most likely to progress to clinical AD [63].

#### **Cerebrospinal fluid biomarkers in normal older people**

While the intention of CSF biomarkers is to diagnose patients with dementia in the prodromal phase and to predict progression in patients with mild symptoms, it has been shown in different cohorts that the characteristic CSF profile of AD can be seen in up to one-third of healthy older individuals [64,65]. Several longitudinal studies have shown that lower CSF A $\beta_{1-42}$  and higher t-tau or p-tau levels, even in healthy subjects at baseline, are correlated with future decline in cognitive functions [66] and faster progression of brain atrophy [67], suggesting that the CSF changes are consistent with the presence of significant AD-P at baseline [68]. In another study, high CSF levels of t-tau or p-tau was correlated with more severe impairment in memory, mental speed, and executive functioning, which is not explained by disease severity, implying that high p-tau or t-tau may reflect a more aggressive disease course [69].

#### **Cerebrospinal fluid versus imaging biomarkers**

In comparison with structural MRI, CSF appears to perform less well in detecting changes over time. While both whole-brain atrophy rate as measured by MRI and CSF levels of A $\beta_{1-42}$ , t-tau, and p-tau all provide complementary information in patients with MCI and AD [70], baseline MRI and fluorodeoxyglucose-PET measures were more responsive to clinical changes than CSF measures in MCI subjects [71-73]. Additionally, structural MRI change was a better predictor of subsequent cognitive/functional change than CSF biomarkers. While MRI and CSF provide complimentary predictive information about the time to conversion from amnesic MCI to AD – with the combination of the two measures resulting in increased predicted power relative to either source alone – it was found that MRI was a better predictor of future clinical/functional decline than

the CSF biomarkers tested [73]. Furthermore, when  $A\beta_{1-42}$  and t-tau are used together, p-tau does not appear to have additional value for the purpose of predicting progression from MCI to AD, although p-tau appears to be more specific to AD pathology and t-tau can be elevated in other neurodegenerative conditions [49]. However, a more recent study found that p-tau decreases at a rate of 2.2 pg/ml/year and correlates better with cognitive functioning than either  $A\beta_{1-42}$  or t-tau, possibly reflecting neuronal loss specific to AD [74].

#### Other potential cerebrospinal fluid biomarkers

In addition to  $A\beta_{1-42}$ , t-tau and p-tau, additional CSF biomarkers have been proposed, although they have yet to be widely replicated. For example, CSF epithelium-derived factor and haptoglobin are measures of oxidative damage, and may help with differentiating AD from other forms of dementia [75]. Sphingomyelin, a class of phospholipids involved in neurodegenerative processes, is significantly elevated in AD compared with controls, with potential utility as an AD biomarker in terms of studying lipid metabolism in the brain. Similarly, lipoprotein receptor (LR11) has been implicated in the pathogenesis of AD, with levels significantly increased in AD compared with controls [76]. In studies using targeted proteomic screening approach, novel biomarkers including C3, CgA, IL-1 $\alpha$ , I-309, NrCAM and vascular endothelial growth factor were found to further improve differentiation between AD and non-AD dementia, with altered levels of IL-1 $\alpha$  and TECK being associated with subsequent cognitive decline [77]. In addition, oligomeric  $A\beta$  species have been implicated in the pathophysiology of AD, and therefore may correlate with the onset of disease. Novel assays of misfolded protein for the detection of soluble  $A\beta_{1-40}$  and  $A\beta_{1-42}$  oligomers in CSF have shown promise in terms of greater accuracy in differentiating patients with MCI and AD from normal controls, as compared with the usual methods based on fibrillar forms of the peptide [15,78].

#### Cerebrospinal fluid biomarkers for non-AD dementias

While there have been extensive efforts in defining biomarkers of AD-P, the need for biomarkers of other forms of dementia may be even more acute. For instance, we now know that FTD is associated with at least three pathological subtypes due to abnormal protein accumulation from tau, from TAR DNA binding protein-43 (TDP-43), and from the RNA-binding protein Fused in Sarcoma (FUS). However, their clinical presentations are highly variable and heterogeneous, which includes behavioral variant FTD, progressive nonfluent aphasia, and semantic dementia, and can often be confused with logopenic and frontal (behavioral) variants of AD. While a number of studies have

demonstrated utility of CSF biomarkers in differentiating AD from FTD variants, few have demonstrated good utility in differentiating between FTD subtypes [52,79]. Targeted multiplex proteomics screening found that Fas, agouti-related peptide, adrenocorticotrophic hormone, and several chemokines (IL-23, IL-17) may have utility in differentiating FTD with TDP-43 accumulation from FTD with tau accumulation [77]. These novel findings require further replication and validation. In the unique case of familial frontotemporal dementia due to progranulin (*PGRN*) mutations that causes a subset of FTD with TDP-43 accumulation (Mackenzie type 1 or type A) pathology, there is emerging evidence that CSF and plasma levels of progranulin may predict the presence of a mutation. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration [21,80]. It is not yet known whether low *PGRN* levels will predict individuals with other subtypes of FTD with TDP-43 accumulation, such as in sporadic cases.

Vascular cognitive impairment and VaD are conditions that often coexist with AD [81]. While some studies have found utility of  $A\beta_{1-42}$ , t-tau and p-tau in differentiating AD from VaD [82], this has not been consistently replicated. This differentiation may, in part, be due to the co-existence of AD and vascular cognitive impairment/VaD in a given study sample. Several studies have found that the elevation of the CSF/serum albumin index may be a useful measure of disruption to the blood-brain barrier due to VaD [83-86]. Another potential biomarker for VaD is CSF sulfatide, an acidic glycopospholipid presented in myelin sheaths of oligodendrocytes that was found to be 200% higher in VaD patients compared with controls and AD patients [87,88]. This marker was found to be decreased in a study of MCI and early AD compared with controls, but its exact mechanism in relation to neurodegenerative disease remains unclear [89]. Neurofilament is a cytoskeletal component concentrated in larger myelinated axons. A few studies found that CSF neurofilament elevation is associated with the presence of white matter changes, whereas CSF neurofilament is normal in AD [90-92]. Other markers of inflammation including IL-6 and metalloproteinase-9 are elevated in VaD or its precursor state, but not in AD [92-96]. A caveat of these inflammatory markers is that they may be influenced by other disease states, for instance viral meningitis, and must be interpreted with caution.

DLB and PDD are also common causes of cognitive decline in older people. Like vascular cognitive impairment and VaD, DLB can often co-exist with AD in patient populations [97]. Several studies have shown that levels of CSF  $A\beta_{1-42}$  are decreased in DLB and PDD, which is also predictive of future cognitive decline [55,77,98,99]. However, in these studies, subjects were

diagnosed clinically without pathological confirmation. It is possible that these patients had mixed AD/DLB, or that DLB pathology *per se* can cause a drop in CSF A $\beta_{1-42}$  levels [100-103]. In contrast, while t-tau and p-tau levels in DLB may be similar or slightly lower than those of controls, they are significantly higher in AD compared with DLB, and therefore can be used to differentiate AD from DLB [104,105]. There is, moreover, emerging evidence that measurement of specific forms of  $\alpha$ -synuclein in CSF may contribute to the diagnosis of PDD and DLB. However, studies have been mixed, and further validation is required before this can be put forward as a diagnostic test for PDD or DLB [103].

### Limitations for the use of biomarkers in clinical practice

Several methodological limitations remain before biomarkers can be applied in clinical practice. While the measurements of CSF concentrations of these biomarkers using enzyme-linked immunosorbent assays (for example, Innogenetics, Ghent, Belgium) or multiplex techniques (for example, xMAP; Luminex) have an acceptably low coefficient of intra-laboratory variability (5 to 10%), the high inter-laboratory variation (20 to 30%) hinders comparison of data generated in different settings [106]. Potential sources of variation include pre-analytical conditions (that is, sample handling and aliquot storing), analytical conditions (different methods), and post-analytical norms for patients for defining the cutoff points (that is, age or apolipoprotein 4 status). Furthermore, the current body of knowledge regarding biomarkers fails to categorize clinical scenarios characterized by ambiguous, indeterminate or conflicting results involving multiple biomarkers.

In summary, while CSF biomarkers in AD and dementia have made significant advances and hold great promise for future application in the clinical setting, we cannot recommend their general use until the above limitations have been rectified. Working groups have been developing protocols to resolve these issues (see [107]).

### Recommendations for CCCDTD4 regarding biomarkers in AD and related dementias

- Plasma amyloid measurements are not recommended for clinical practice (Grade 1B).
- CSF biomarkers are not recommended in the diagnosis of AD to evaluate subjects with typical clinical presentation of AD (Grade 2A).
- CSF biomarkers are not recommended for screening of normal healthy subjects for the purpose of assessing future risk of developing AD (Grade 1B).
- CSF biomarkers can be considered in special cases in which there are atypical features or diagnostic

confusion, such as differentiating frontal variants of AD from FTD, or cases of progressive aphasia, which may be due to AD-P or FTD pathology (Grade 2B).

- In specialized settings, CSF biomarkers can be considered to improve diagnostic certainty and prognostication in mild cognitive impairment or possible AD; for example, when considering participation in a clinical research study (Grade 1B).
- If a decision to obtain CSF biomarkers is made, a combination of A $\beta_{1-42}$ , total tau, and/or p-tau measurements should be used (Grade 2A).
- We recommend that biomarkers analysis must be performed under a standardized protocol at a centralized and certified facility (commercial or academic) with a track record in producing high-quality, consistent data, and interpreted by specialists with expertise on the field of fluid biomarkers (Grade 1B).

### Abbreviations

AD, Alzheimer's disease; AD-P, Alzheimer's pathology; APP, amyloid precursor protein; CCCDTD4, Fourth Canadian Consensus Conference on Diagnosis and Treatment of Dementia; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; IL, interleukin; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PDD, Parkinson's disease with dementia; PET, positron emission tomography; p-tau, phosphorylated tau (nonspecified); TDP-43, TAR DNA binding protein-43; t-tau, total tau; VaD, vascular dementia.

### Competing interests

The authors declare that they have no competing interests.

### Acknowledgements

Sincere thanks to the staff of Medplan who helped prepare the numerous teleconferences prior to and the logistics of the CCCDTD4 meeting, as well as the staff of the McGill Center for Studies in Aging who helped during the meeting in Montreal. PR-N was supported by the Alzheimer's Association new investigator grant, Fonds de la Recherche en Santé du Québec, Chercheur Burcier award and Canadian Institutes of Health Research (CIHR). MM receives research support from the Parkinson Society Canada, CIHR, Ministry of Economic Development and Innovation of Ontario, Consortium of Canadian Centres for Clinical Cognitive Research (C5R) and Teva Pharmaceuticals, and salary support from the Department of Medicine (Sunnybrook HSC and University of Toronto), and the Sunnybrook Foundation.

CCDTD4 participants: A Al Rashed, R Bartha, H Bergman, J Bethell, S Black, C Bocti, M Borrie, A Burham, H Chertkow, C Cook, J Crowson, M Donnelly, H Feldman, S Gauthier, M Gordon, G Heckman, N Herrmann, D Hogan, GYR Hsiung, G Inglis, C Jacova, R Laforce, K Lanctot, L Lee, K Leclair, M Masellis, F Massoud, A Moore, C Patterson, S Prasad, K Rabheru, K Rockwood, D Sadovnick, JP Soucy, L Trudeau, I Vedel, M Williams.

### Author details

<sup>1</sup>McGill Centre for Studies in Aging, McGill University, 6825 LaSalle Boulevard, Verdun, Montreal, Quebec, Canada H4H 1R3. <sup>2</sup>Douglas Research Institute, McGill University, 6875 LaSalle Blvd, FBC room 1144, F-0105 Montréal (Verdun), QC, Canada H4H 1R3. <sup>3</sup>Division of Neurology, Department of Medicine, University of British Columbia, S162 - 2211 Wesbrook Mall, UBC Hospital, Vancouver BC, Canada V6T 2B5. <sup>4</sup>L.C. Campbell Cognitive Neurology Research Unit, Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue Toronto, Ontario, Canada M4N 3M5. <sup>5</sup>Department of Medicine, Division of Neurology, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada. <sup>6</sup>Neurogenetics Section, Centre for Addiction and Mental Health (Queen and Ossington) 1001 Queen Street West; 30, 40, 50 and 60 White Squirrel Way; 100 and 101 Stokes Street; 80 Workman Way, Toronto, Ontario M6J 1H4, Canada.

Published: 25 November 2013

## References

- Serrano-Pozo A, Froesch MP, Masliah E, Hyman BT: **Neuropathological alterations in Alzheimer disease.** *Cold Spring Harb Perspect Biol* 2011, **3**:1-23.
- Blennow K, Zetterberg H, Fagan AM: **Fluid biomarkers in Alzheimer disease.** *Cold Spring Harb Perspect Biol* 2012, **2**:1-23.
- Biomarkers Definitions Working Group: **Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.** *Clin Pharmacol Ther* 2001, **69**:89-95.
- Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: **Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.** *Lancet Neurol* 2009, **9**:119-128.
- Blennow K, Hampel H, Weiner M, Zetterberg H: **Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.** *Nat Rev Neurol* 2010, **6**:131-144.
- Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O'Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, Dearmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ: **Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.** *Neurology* 2011, **77**:2034-2042.
- Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O'Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML: **A $\beta$  amyloid and glucose metabolism in three variants of primary progressive aphasia.** *Ann Neurol* 2008, **64**:388-401.
- Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME: **Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.** *JAMA* 2001, **286**:2120-2127.
- Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH: **Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.** *Alzheimers Dement* 2011, **7**:257-262.
- Hardy JA, Higgins GA: **Alzheimer's disease: the amyloid cascade hypothesis.** *Science* 1992, **256**:184-185.
- Hardy J: **Testing times for the 'amyloid cascade hypothesis'.** *Neurobiol Aging* 2002, **23**:1073-1074.
- Haass C, Selkoe DJ: **Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid  $\beta$ -peptide.** *Nat Rev Mol Cell Biol* 2007, **8**:101-112.
- Ikonomic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST: **Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.** *Brain* 2008, **131**:1630-1645.
- Seeman P, Seeman N: **Alzheimer's disease: beta-amyloid plaque formation in human brain.** *Synapse* 2011, **65**:1289-1297.
- Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S: **A $\beta$ 40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.** *PLoS ONE* 2010, **5**:e15725.
- Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M: **High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.** *Faseb J* 2010, **24**:2716-2726.
- Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL: **Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls.** *Ann Neurol* 2013, **73**:104-119.
- Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ: **New ELISAs with high specificity for soluble oligomers of amyloid  $\beta$ -protein detect natural A $\beta$  oligomers in human brain but not CSF.** *Alzheimers Dement* 2013, **9**:99-112.
- Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BNM: **Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.** *J Nucl Med* 2009, **50**:1464-1470.
- Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative: **Transforming cerebrospinal fluid A $\beta$ 42 measures into calculated Pittsburgh compound B units of brain A $\beta$ 42; amyloid.** *Alzheimers Dement* 2011, **7**:133-141.
- Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Biscoglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R: **Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.** *Brain* 2009, **132**:583-591.
- Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB: **Plasma clusterin and the risk of Alzheimer disease.** *JAMA* 2011, **305**:1322-1326.
- Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I: **Evaluation of plasma A $\beta$  as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.** *J Alzheimers Dis* 2012, **28**:231-238.
- Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Frölich L, Henn F, Falkai P, Rütger E, Jahn H, Luckhaus Ch, Pernecky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J: **Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing.** *Exp Neurol* 2010, **223**:366-370.
- Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gyllys KH, Varpetian A, Medina LD, Cummings JL: **Biochemical markers in persons with preclinical familial Alzheimer disease.** *Neurology* 2008, **71**:85-92.
- Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R: **Elevated plasma beta-amyloid peptide A $\beta$ (42) levels, incident dementia, and mortality in Down syndrome.** *Arch Neurol* 2007, **64**:1007-1013.
- Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C: **Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.** *Neurobiol Aging* 2006, **27**:904-905.
- Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londo E, Wallin A, Minthon L, Blennow K: **Evaluation of plasma A $\beta$ (40) and A $\beta$ (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.** *Neurobiol Aging* 2010, **31**:357-367.
- Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F: **Plasma amyloid- $\beta$  as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.** *Arch Neurol* 2012, **69**:824-831.
- Galasko D, Golde TE: **Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems.** *Alzheimers Res Ther* 2013, **5**:1-5.
- Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW: **A protein factor essential for microtubule assembly.** *Proc Natl Acad Sci U S A* 1975, **72**:1858-1862.
- Hall GF, Lee VM, Kosik KS: **Microtubule destabilization and neurofilament phosphorylation precede dendritic sprouting after close axotomy of lamprey central neurons.** *Proc Natl Acad Sci U S A* 1991, **88**:5016-5020.
- Mattsson N, Zetterberg H, Hansson O, Andreassen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K: **CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.** *JAMA* 2009, **302**:385-393.
- Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW: **Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.** *Neurology* 2010, **74**:201-209.
- Zetterberg H, Hietala MA, Jonsson M, Andreassen N, Styrd E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A: **Neurochemical aftermath of amateur boxing.** *Arch Neurol* 2006, **63**:1277-1280.
- Ost M, Nylén K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B: **Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury.** *Neurology* 2006, **67**:1600-1604.
- Hesse C, Rosengren L, Andreassen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K: **Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.** *Neurosci Lett* 2001, **297**:187-190.
- Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekinen P, Soininen H: **CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.** *Neurology* 1998, **50**:169-174.

39. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: **Evaluation of CSF-tau and CSF-A $\beta$ 42 as diagnostic markers for Alzheimer disease in clinical practice.** *Arch Neurol* 2001, **58**:373-379.
40. Blennow K, Hampel H, Weiner M, Zetterberg H: **Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.** *Nat Rev Neurol* 2010, **6**:131-144.
41. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP; CCCDTD4 participants: **4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.** *Can J Neurol Sci* 2012, **39**(6 Suppl 5):S1-S8.
42. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy J-P: **Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDT4).** *Can Geriatr J* 2012, **15**:120-126.
43. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ: **Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.** *BMJ* 2008, **336**:924.
44. Hort J, Bartos A, Pirttilä T, Scheltens P: **Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.** *Eur J Neurol* 2010, **17**:90-96.
45. Kang J-H, Vanderstichele H, Trojanowski JQ, Shaw LM: **Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.** *Methods* 2012, **56**:484-493.
46. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K: **Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative.** *Alzheimers Dement* 2012, **8**:65-73.
47. Reiber H: **Dynamics of brain-derived proteins in cerebrospinal fluid.** 2001, **310**:173-186.
48. Bateman RJ, Munsell LY, Morris JC, Swann R, Yarasheski KE, Holtzman DM: **Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.** *Nat Med* 2006, **12**:856-861.
49. Trojanowski JQ, Vanderstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM: **Alzheimer's Disease Neuroimaging Initiative: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.** *Alzheimers Dement* 2010, **6**:230-238.
50. Jack Jr CR, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW: **Alzheimer's Disease Neuroimaging Initiative: Update on the magnetic resonance imaging core of the Alzheimer's Disease Neuroimaging Initiative.** *Alzheimers Dement* 2010, **6**:212-220.
51. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkmann D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K: **Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.** *Arch Gen Psychiatry* 2004, **61**:95-102.
52. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehericy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M: **Similar amyloid- $\beta$  burden in posterior cortical atrophy and Alzheimer's disease.** *Brain* 2011, **134**:2036-2043.
53. Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T: **Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.** *Arch Neurol* 2009, **66**:382-389.
54. Bastard NL, Martin J-J, Vanmechelen E, Vanderstichele H, Deyn PPD, Engelborghs S: **Added diagnostic value of CSF biomarkers in differential dementia diagnosis.** *Neurobiol Aging* 2010, **31**:1867-1876.
55. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YAL, van Elk EJ, Scheltens P, van der Flier WM: **CSF biomarkers predict rate of cognitive decline in Alzheimer disease.** *Neurology* 2009, **73**:1353-1358.
56. Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YAL, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM: **Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.** *Neurology* 2011, **78**:47-54.
57. Hansson O, Zetterberg H, Buchhave P, Londo E, Blennow K, Minthon L: **Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.** *Lancet Neurol* 2006, **5**:228-234.
58. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A: **Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.** *Mol Psychiatry* 2003, **8**:343-347.
59. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group: **Biomarkers for Alzheimer's disease therapeutic trials.** *Prog Neurobiol* 2011, **95**:579-593.
60. van Rossum IA, Vos S, Handels R, Visser PJ: **Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.** *J Alzheimers Disease* 2010, **20**:881-891.
61. Hertzze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O: **Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years.** *J Alzheimers Dis* 2010, **21**:1119-1128.
62. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund L-O, Lannfelt L, Ingelsson M: **Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.** *Dement Geriatr Cogn Disord* 2009, **27**:458-464.
63. Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative: **Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.** *Neurobiol Aging* 2010, **31**:1443-1451, 1451.e1.
64. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K: **Cerebrospinal fluid levels of total-tau, phospho-tau and A $\beta$ 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.** *Acta Neurol Scand* 2003, **107**:47-51.
65. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative: **Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.** *Arch Neurol* 2010, **67**:949-956.
66. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson S-E, Lindau M, Eriksdotter-Jonhagen M: **Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.** *Neurobiol Aging* 2008, **29**:1466-1473.
67. Tosun D, Schuff N, Truran-Sacrety D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative: **Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.** *Neurobiol Aging* 2010, **31**:1340-1354.
68. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM: **CSF biomarker levels in early and late onset Alzheimer's disease.** *Neurobiol Aging* 2009, **30**:1895-1901.
69. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM: **CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.** *Neurology* 2009, **72**:1056-1061.
70. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P: **Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.** *Neurobiol Aging* 2010, **31**:758-764.
71. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative: **CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.** *J Neurosci* 2010, **30**:2088-2101.
72. Arlt S, Brassen S, Jahn H, Wilke F, Eichenlaub M, Apostolova I, Wenzel F, Thiele F, Young S, Buchert R: **Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.** *Eur J Nucl Med Mol Imaging* 2009, **36**:1090-1100.
73. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative: **MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.** *Neurology* 2009, **73**:294-301.
74. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka S-K: **Longitudinal changes of CSF biomarkers in Alzheimer's disease.** *J Alzheimers Disease* 2011, **25**:583-594.
75. Abraham J-D, Calvayrac-Pawlowski S, Cobo S, Salvétat N, Vicat G, Molina L, Touchon J, Michel BF, Molina F, Verdier JM, Fareh J, Mourton-Gilles C: **Combined measurement of PEDF, haptoglobin and tau in cerebrospinal**

- fluid improves the diagnostic discrimination between Alzheimer's disease and other dementias. *Biomarkers* 2011, **16**:161-171.
76. Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma H, Takubo K, Kaneko H, Kasuga K, Kakita A, Takahashi H, Bujo H, Saito Y, Nishizawa M: **Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease.** *Dement Geriatr Cogn Disord* 2010, **30**:28-32.
  77. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ: **Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.** *Acta Neuropathol* 2010, **119**:669-678.
  78. Santos AN, Ewers M, Minthon L, Simm A, Silber R-E, Blennow K, Prvulovic D, Hansson O, Hampel H: **Amyloid- $\beta$  oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.** *J Alzheimers Dis* 2012, **29**:171-176.
  79. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rütger E, Wiltfang J: **Cerebrospinal fluid tau, p-tau 181 and amyloid- $\beta$ 38/40/42 in frontotemporal dementias and primary progressive aphasia.** *Dement Geriatr Cogn Disord* 2011, **31**:37-44.
  80. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G: **Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration.** *Neurology* 2008, **71**:1235-1239.
  81. Woodward M, Mackenzie IRA, Hsiung GYR, Jacova C, Feldman H: **Multiple brain pathologies in dementia are common.** *Eur Geriatr Med* 2010, **1**:259-265.
  82. de Jong D, Jansen RWMM, Kremer BPH, Verbeek MM: **Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.** *J Gerontol A Biol Sci Med Sci* 2006, **61**:755-758.
  83. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF: **Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.** *Neurology* 2007, **68**:1809-1814.
  84. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV: **Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants.** *Arch Neurol* 2009, **66**:208-215.
  85. Wallin ÅK, Hansson O, Blennow K, Londo E, Minthon L: **Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?** *Int J Geriatr Psychiatry* 2009, **24**:638-647.
  86. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreassen N, Grundke-Iqbal I, Iqbal K: **Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease.** *J Alzheimers Dis* 2011, **25**:505-515.
  87. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L: **Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia.** *Acta Neurol Scand* 1992, **85**:103-106.
  88. Tullberg M, Månsson J-E, Fredman P, Lekman A, Blennow K, Ekman R, Rosengren LE, Tisell M, Wikkelso C: **CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy.** *J Neurol Neurosurg Psychiatry* 2000, **69**:74-81.
  89. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM: **Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia.** *Ann Neurol* 2003, **54**:115-119.
  90. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A: **Subcortical vascular dementia biomarker pattern in mild cognitive impairment.** *Dement Geriatr Cogn Disord* 2009, **28**:348-356.
  91. Wallin A, Sjogren M: **Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia.** *Mech Ageing Dev* 2001, **122**:1937-1949.
  92. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U: **Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.** *J Alzheimers Dis* 2011, **27**:665-676.
  93. Rosenberg GA, Sullivan N, Esiri MM: **White matter damage is associated with matrix metalloproteinases in vascular dementia.** *Stroke* 2001, **32**:1162-1168.
  94. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA: **Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.** *Stroke* 2004, **35**:e159-e162.
  95. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E: **Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.** *J Neurol* 2008, **255**:539-544.
  96. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: **Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.** *Neurosci Lett* 1995, **202**:17-20.
  97. Woodward M, Brodaty H, Boundy K, Ames D, Blanch G, Balshaw R: **Does executive impairment define a frontal variant of Alzheimer's disease?** *Int Psychogeriatr* 2010, **22**:1280-1290.
  98. Johansen KK, White LR, Sando SB, Aasly JO: **Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies.** *Parkinsonism Relat Disord* 2010, **16**:307-315.
  99. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T: **Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.** *J Neurol Neurosurg Psychiatry* 2010, **81**:608-610.
  100. Alves G, Brønneck K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes O-B, Larsen JP, Mulugeta E: **CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.** *J Neurol Neurosurg Psychiatry* 2010, **81**:1080-1086.
  101. Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Cho MK, Rios J, Tolosa E: **Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.** *Mov Disord* 2009, **24**:2203-2210.
  102. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M: **Total tau protein, phosphorylated tau (181p) protein,  $\beta$ -amyloid1-42, and  $\beta$ -amyloid1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies.** *Clin Chem Lab Med* 2006, **44**:192-195.
  103. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki H-W, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rütger E, Kornhuber J, Otto M, Wiltfang J: **CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.** *Brain* 2006, **129**:1177-1187.
  104. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P: **Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.** *Biol Psychiatry* 2008, **64**:850-855.
  105. Otto M, Lewczuk P, Wiltfang J: **Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.** *Methods* 2008, **44**:289-298.
  106. Mattsson N, Blennow K, Zetterberg H: **Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.** *Clin Chem Lab Med* 2010, **48**:603-607.
  107. Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K: **Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.** *Biomark Med* 2012, **6**:401-407.

doi:10.1186/alzrt223

Cite this article as: Rosa-Neto P, et al.: Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. *Alzheimer's Research & Therapy* 2013, **5**(Suppl 1):S8.